Company / Revenue
C4 Therapeutics, Inc. Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$35.9M
FY2025
5-year range
$20.8M / $45.8M
FY2022-FY2025
Trend
+73.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $21M to $36M over the past 2 years.
Based on SEC 10-K filings.
$36M in FY2025 with a 3-year CAGR of -7.7%.
Improved from $21M to $36M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -7.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -7.7%, indicating a declining trend.
- In FY2025, revenue increased 73.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.9M | +73.2% |
| FY2024 | $20.8M | +0.0% |
| FY2023 | $20.8M | -54.7% |
| FY2022 | $45.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026